<DOC>
	<DOCNO>NCT02943343</DOCNO>
	<brief_summary>The China Pulmonary Thromboembolism Registry Study ( CURES ) prospective multicenter registry project initiate January 2008 consist obtain extensive data registry consecutive patient pulmonary thromboembolism . - The main objective registry study help physician improve knowledge natural history pulmonary thromboembolism , include epidemiological characteristic , personal history , risk factor , clinical manifestation , diagnostic method , therapeutic regimen , clinical outcome , prognosis , etc.. - Secondly , study also aim find useful information patient usually recruit randomized clinical trial ( pregnant woman , elderly patient , disseminate cancer , severe renal insufficiency , patient contraindication anticoagulation therapy , extreme body weight , etc ) . - Thirdly , ultimate purpose CURES study decrease mortality , frequency thromboembolic recurrence well bleed complication arterial event .</brief_summary>
	<brief_title>The China Pulmonary Thromboembolism Registry Study</brief_title>
	<detailed_description>The China Pulmonary Thromboembolism Registry Study ( CURES ) prospective multicenter registry study initiate January 2008 consist obtain extensive data registry consecutive patient pulmonary thromboembolism across P.R . China . This study three-stage design : - Stage I : January 2008 June 2011 , CURES study consecutively enrol 3,000 eligible pulmonary thromboembolism patient without follow-up ; - Stage II : July 2011 July 2016 , CURES study continue enroll 5,000 objectively confirm pulmonary thromboembolism patient three month follow-up ; - Stage III : August 2016 December 2019 , CURES study plan enroll 3,000 pulmonary thromboembolism patient least three month follow-up , well collect blood sample thromboembolism relevant biomarkers genetic background .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<criteria>Confirmed pulmonary thromboembolism ( acute pulmonary thromboembolism and/or deepvein thrombosis , superficial venous thrombosis ) objective test ; Informed consent participation study , accord requirement ethic committee within hospital . Age &lt; 18 year ; Participation therapeutic clinical trial unknown drug ; Inability three month followup ; Suspected venous thromboembolism/pulmonary thromboembolism patient admit hospital whereas without confirm evidence ( image pathology ) disease ; The ever venous thromboembolism/pulmonary thromboembolism patient readmitted hospital examination treatment whereas without evidence disease recurrence .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>